ANRO (ANRO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

ANRO (ANRO) closed at USD 21.71 on 2026-10-14, a change of +59.4 % over the past year, with a market capitalization of USD 887.66M.

ANRO recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

ANRO key figures

Previous close

USD 21.71 (2026-10-14)

1-year change

+59.4 %

Market cap

USD 887.66M

Enterprise value

USD 667.22M

P/E ratio (trailing)

-9.97

P/E ratio (forward)

-6.88

EPS (trailing)

-2.27

EPS (forward)

-3.29

PEG ratio

n/a

Price to book

3.62

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.73

Employees

68

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About ANRO

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for ANRO and compare it with other stocks.